HeartBeam (Nasdaq:BEAT) today announced that a study of its synthesized 12-lead electrocardiogram (ECG) met its clinical ...

The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam's synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in assessing ...

SANTA CLARA, Calif., April 29, 2025--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights ...

Data showed a 93.4% overall diagnostic agreement, indicating that HeartBeam’s synthesized 12-lead ECG can support diagnosis of arrhythmias in a manner consistent with standard 12-lead ECGs. "This ...

Milestone results formed the basis of HeartBeam’s 12-lead ECG synthesis software application submitted to FDA in January 2025 SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a ...

This is the offical code repository accompanying our paper on Self-supervised representation learning from 12-lead ECG data. For a detailed description of technical details and experimental results, ...

HeartBeam rolled out an application for its 12-lead ECG synthesis software to the FDA, based on the data from the study.

The purpose of this study was to evaluate whether the 12-lead ECG could be substituted by ECG sets with a limited number of leads. Materials and methods: The performance of three ECG systems (ie ...

Every year, some mothers die after giving birth due to heart problems, and many of these deaths could be prevented. The ...

Every year, some mothers die after giving birth due to heart problems, and many of these deaths could be prevented. The ...

Persistent Link: https://ieeexplore.ieee.org/servlet/opac?punumber=92 ...